Pharmaceuticals News and Research

RSS

WisTa Laboratories announces collaborative R&D agreement with Bayer Schering Pharma

WisTa Laboratories Ltd, a wholly owned subsidiary of TauRx Pharmaceuticals, announced today that they have entered a collaborative R&D agreement with Bayer Schering Pharma AG, Germany, which could redefine the way Alzheimer's disease (AD) and related disorders are currently being diagnosed and treated.

4 Jun 2010

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide.

4 Jun 2010

Millipore shareholders approve acquisition of all outstanding shares of common stock by Merck KGaA

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced that its shareholders voted at a Special Meeting of Shareholders to approve the previously-announced acquisition of all outstanding shares of common stock of Millipore by Merck KGaA of Germany, the global pharmaceutical and chemical company.

4 Jun 2010

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Intellect Neurosciences, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent related to the Company's humanized monoclonal antibody, IN-N01, being developed as a disease-modifying treatment for Alzheimer's disease and other related indications.

4 Jun 2010

European countries focus on drug price cuts

"European governments grappling to reduce large budget deficits are focusing their cost-cutting on a large spending item — pharmaceuticals," The Wall Street Journal reports. "Several countries in recent weeks, including Spain, Germany and Italy, have proposed or enacted reductions in what they will pay or taken other cost-control measures for various drugs.

4 Jun 2010

Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome

Tioga Pharmaceuticals, Inc. announced today that the company has dosed its first subject in a Phase 3 clinical trial to evaluate asimadoline for the treatment of patients with diarrhea-predominant irritable bowel syndrome (DIBS). The trial, referred to as ASMP3001, is the first of two Phase 3 trials being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for U.S. registration. This first trial will be conducted at 120 sites in the U.S.

4 Jun 2010

Malvern publishes online chemical imaging bibliography

By combining conventional spectroscopy with sophisticated mapping and imaging technology in its SyNIRgi chemical imaging system and ISys chemical imaging software, Malvern Panalytical has greatly extended the application of vibrational spectroscopy.

From Malvern Panalytical 3 Jun 2010

Taro's granisetron tablets receive FDA approval

Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").

3 Jun 2010

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 Jun 2010

First Edition: June 3, 2010

Today's headlines reflect news regarding health reform and the budget deficit as well as a new ad campaign by the AMA to press Senators to approve a freeze on scheduled Medicare payment cuts.

3 Jun 2010

Researchers identify new therapeutic target for cognitive decline

Researchers at Mount Sinai School of Medicine have found that certain types of specializations on nerve cells called "spines" are depleted as a person ages, causing cognitive decline in the part of the brain that mediates the highest levels of learning.

3 Jun 2010

Tamro Group's first-quarter 2010 net sales increase 7.4% to EUR 1,424 million

Tamro Group's net sales in February-April 2010 amounted to EUR 1,424 million, an increase of 7.4%. A significant part of the sales increase is due to strengthened exchange rates of the Swedish, Norwegian and Polish currencies. At constant exchange rates, Tamro's net sales increased by 1.8%.

3 Jun 2010

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Novartis Pharmaceuticals Corporation announced today that a Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors.

3 Jun 2010

Discovery provides new therapeutic target to prevent brain function loss

3 Jun 2010

Academic detailing technique may help doctors follow treatment guidelines

Researchers often get frustrated when doctors fail to adopt treatment guidelines backed by the best evidence-based research.

3 Jun 2010

FDA accepts Eisai's NDA for rabeprazole sodium extended-release 50 mg

Eisai Inc. (Headquarters: Woodcliff Lake, NJ; Chairman and CEO: Hajime Shimizu), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today announced that the U.S. Food and Drug Administration has accepted Eisai's New Drug Application for rabeprazole sodium extended-release 50 mg for the healing and maintenance of healing of erosive gastroesophageal reflux disease, and for the treatment of symptomatic GERD.

3 Jun 2010

Bangalore INDIA BIO 2010 inaugurated

Bangalore INDIA BIO 2010, India's premier Biotechnology event organized by the Department of Information Technology, Biotechnology and Science & Technology, Government of Karnataka, Vision Group on Biotechnology and MM Activ Sci-Tech Communications Co was inaugurated today by Shri B.S. Yeddyurappa, Hon'ble Chief Minister of Karnataka, and Shri Katta Subramanya Naidu - Hon'ble Minister for IT & BT, Information, Excise and BWSSB, Government of Karnataka.

2 Jun 2010

Cantel Medical acquires Texas-based Purity Water

CANTEL MEDICAL CORP., through its Mar Cor Purification subsidiary, has continued the expansion of its water purification and filtration segment by purchasing Texas-based Purity Water Company of San Antonio, Inc. Purity provides water treatment equipment and services for laboratory, industrial, medical, pharmaceutical and semiconductor customers in Texas and neighboring states. The acquired business had pre-acquisition revenues of approximately $3.0 million.

2 Jun 2010

Axcan extends use of Medidata Rave as EDC and CDM system

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that Axcan Pharma Inc. has extended its use of Medidata Rave as its electronic data capture and clinical data management system, bringing study build and execution into the organization through Medidata training and mentoring.

2 Jun 2010

Perrigo acquires rights to Novel Laboratories' pending ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

Perrigo Company announced on May 26, 2010 that it had acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets).

2 Jun 2010

Pharmaceuticals News and Research

WisTa Laboratories announces collaborative R&D agreement with Bayer Schering Pharma

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

Millipore shareholders approve acquisition of all outstanding shares of common stock by Merck KGaA

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

European countries focus on drug price cuts

Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome

Malvern publishes online chemical imaging bibliography

Taro's granisetron tablets receive FDA approval

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

First Edition: June 3, 2010

Researchers identify new therapeutic target for cognitive decline

Tamro Group's first-quarter 2010 net sales increase 7.4% to EUR 1,424 million

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Discovery provides new therapeutic target to prevent brain function loss

Academic detailing technique may help doctors follow treatment guidelines

FDA accepts Eisai's NDA for rabeprazole sodium extended-release 50 mg

Bangalore INDIA BIO 2010 inaugurated

Cantel Medical acquires Texas-based Purity Water

Axcan extends use of Medidata Rave as EDC and CDM system

Perrigo acquires rights to Novel Laboratories' pending ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

Pittcon Highlights: Pharmaceutical & Biologic eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News